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Abstract: 
 
 Collateral dependent hyperemia is reduced following chronic ischemia, but the 
contribution of individual vessel reactivity is unknown. Further, it is not known what 
aspect of the complex ischemic injury response impacts vascular reactivity. To determine 
the impact of ischemia on vascular reactivity, we measured functional vasodilation in the 
muscular branch artery following resection of the femoral artery proximal to the muscular 
branch. On day-14 after surgery the diameter of the muscular branch was measured using 
side-stream dark field (SDF) imaging intravital microscopy. At moderate intensity 
skeletal muscle contraction (1mA, 200µs, 8Hz, 90sec), functional vasodilation is reduced 
compared to the contralateral non-ischemic limb (10.84 ± 8.79% versus 151.70 ± 22.15% 
increase above baseline). Conversely, at high intensity skeletal muscle contraction (1mA, 
500µs, 8Hz, 90sec), the initial vasodilation is not different from the contralateral limb, 
but the ischemic arteries are refractory to regaining their resting diameter. The control 
artery returned to baseline diameter within 10-minutes following high-intensity muscle 
contraction, while the ischemic artery did not return to baseline after 25 minutes. Further 
investigation is underway to determine if endothelial or smooth muscle dysfunction 
underlies this abnormal reactivity in ischemic arteries. 
	   5	  
Introduction: 
 	   Chronic	  limb	  ischemia	  (CLI)	  is	  a	  narrowing	  or	  occlusion	  of	  blood	  vessels	  resulting	  in	  an	  insufficient	  blood	  flow	  that	  does	  not	  meet	  metabolic	  demands	  of	  tissue	  [1].	  This	  is	  characterized	  by	  pain	  at	  rest	  and	  ulceration	  or	  gangrene	  of	  ischemic	  tissues	  [2].	  The	  main	  cause	  of	  chronic	  limb	  ischemia	  is	  advanced	  Peripheral	  Arterial	  Disease	  (PAD)	  [2].	  PAD	  is	  a	  type	  of	  atherosclerosis,	  a	  hardening	  and	  narrowing	  of	  the	  arteries	  that	  supply	  blood	  to	  the	  arms	  and	  legs	  [2].The	  development	  of	  arterial	  atherosclerosis	  may	  occur	  when	  deposits	  of	  cholesterol	  and	  plaque	  accumulate	  at	  a	  tear	  in	  the	  inner	  lining	  of	  an	  artery	  [3].	  As	  the	  deposits	  harden	  and	  occlude	  the	  arterial	  lumen,	  blood	  flow	  to	  distant	  tissues	  decreases	  and	  a	  thrombus	  or	  clot	  may	  completely	  occlude	  the	  artery,	  Figure	  1	  [3].	  Smoking,	  diabetes,	  high	  cholesterol,	  high	  blood	  pressure,	  and	  genetic	  history	  all	  increase	  the	  risk	  of	  developing	  PAD	  [1].	   	  
	  
Figure	  1:	  Schematic	  of	  the	  progression	  of	  atherosclerosis  
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 Due to these common risk factors, PAD affects 10-25% of patients over the age of 
55 [4]. From this population, there are 500 to 1000 persons per million per year 
diagnosed with chronic limb ischemia (CLI) [5]. Patients with CLI have a 300% greater 
risk of myocardial infarction [5].  PAD  is also a predictor and co-morbidity for Coronary 
Artery Disease (CAD) where 79% of patients with PAD have CAD [6]. Since PAD 
affects such a large percentage of the adult aged population there has been a substantial 
effort to study the causes and develop treatments for the disease. 
 In patients with advanced PAD surgical intervention may be the necessary for of 
treatment. Angioplasty is used as a minimally-invasive method to mechanically expand 
blocked arteries [7], however, by-pass of blocked arteries is performed in severe cases of 
PAD [7]. Both these involve the mechanical manipulation of the blood vessels to treat 
PAD. Non-invasive treatments are needed to avoid the complexities of surgery and 
provide improved efficacy. Studies focusing on the promotion of vascular growth and 
vascular function to treat PAD are a vital to advancing the treatment of the disease. 
 When ischemia occurs, stimuli for revascularization are derived from the 
ischemic tissue and the walls of vessels supplying the affected region [8]. The remodeling 
processes that occur as a result of these stimuli are known as angiogenesis and 
arteriogenesis [2]. Angiogenesis is the growth of new capillaries from existing capillaries 
through endothelial cell proliferation and migration [9]. Vascular endothelial growth 
factor (VEGF) and fibroblast growth factor (FGF) are the principal molecules involved in 
this process [8]. Various pathways lead to the release of VEGF and FGF [8]. 
Arteriogenesis is described as the outward remodeling or enlargement of preexisting 
vessels into functional collateral arteries [10]. Increased fluid stress and inflammation is 
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thought to be responsible for initiating collateral artery growth [2]. 
 Patients suffering from ischemia demonstrate endothelial dysfunction resulting in 
impaired vasodilation or vasoconstriction referred to as vasoactivity and an insufficient 
vascular growth response [11]. Ischemia alters hemodynamics, causes inflammation, and 
hypoxia, these conditions combine to induce cell necrosis and a complex injury response 
[12]. One way to address this clinical problem is by stimulating the growth response. 
Current clinical and preclinical research is underway to explore treating PAD with the 
stimulation of new blood vessel growth called therapeutic neovasculariztion [2, 10, 13]. 
Many of these studies focus on the growth process and how vessels can be stimulated or 
tissue engineered [2, 10, 13]. However, few focus on the vascular reactivity and blood 
flow during and following the growth process. Proper function must be emphasized in 
order to ensure proper blood flow control is present when new vessels are grown or 
engineered. 
 In order to understand vascular reactivity and blood flow the structure and 
function of the blood vessels needs to be understood. There are three principle categories 
of blood vessels- arteries, veins, and capillaries [14]. The walls of arteries are composed 
of three layers called tunics [14]. The tunica interna lines the inside of the vessel and is 
exposed to blood and consists of the endothelium [14]. The tunica media is the middle 
layer and consists of smooth muscle cells, collagen, and in some cases elastin [14]. The 
tunica externa is the outermost layer, and consists of loose connective tissue that often 
merges with that of neighboring blood vessels nerves and other organs [14]. The veins 
consist of the same basic structure as the arteries, however, they are thin walled and 
contain valves, Figure 2 [14]. The capillaries are composed of an endothelium and 
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basement membrane [14]. Capillaries are extremely thin walled consisting of only a 
single endothelial cell layer allowing for oxygen and nutrient exchange to occur [14]. The 
cells most relevant to vasoactivity and proper function are the endothelium and smooth 
muscles cells of the arteries and arterioles [8].  
 
Figure 2: Artery and Vein Structure 
 There are many signaling processes that control the vasoconstriction and 
vasodilation of the arteries and arterioles [8]. Smooth muscle cells ultimately determine 
diameter, however, smooth muscle can be controlled by endothelial-derived factors, 
neurons, and interstitial compounds [8]. One common pathway for vasoconstriction of 
arteries and arterioles is the release of norepinephrine from sympathetic nervous system 
neurons, which binds to adrenoreceptors on the plasma membrane of vascular smooth 
muscles cells and initiates contraction [8]. A potent and prominent vasodilator is Nitric 
Oxide (NO), which is produced by NOS in endothelial cells in response to a variety of 
stimuli, such as shear stress, neurotransmitters, and paracrine factors, such as bradykinin 
	   9	  
and acetylcholine (Ach) [8]. NO signals the smooth muscle to relax, causing vasodilation 
[8]. Changes in metabolic demand in skeletal muscle influenced by activities such as 
exercise also regulate vasoactivity causing vasodilation at the area of activity [8]. 
Mechanisms of local control also involve myogenic activity and paracrine and blood-
derived factors [8]. Alterations and abnormal functions in vasoactivity following 
ischemia may be due to the change in any of these signaling pathways for 
vasoconstriction and vasodilation. 
 Vascular growth processes are stimulated as a treatment to supply blood to 
ischemic regions[2]. However, it is not only the ability to stimulate vascular growth that 
is relevant to the treatment of ischemic injury. A combination of stimulating vascular 
growth and proper vasodilation could be essential for successful therapeutic 
neovascularization [15]. Therefore, it is vital to understand the underlying mechanisms 
and alterations of vasoactivity as a response to ischemic injury.  
 The purpose of this research is to determine how chronic ischemia affects 
functional vasodilation. It is hypothesized that following an ischemic injury there will be 
an alteration in arterial vasoactivity. Using a mouse model with a resected femoral artery, 
the affects of an ischemic injury will be studied to determine if vasoactivity is altered.  
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Methods: 
Husbandry 
 Male C57/Bl6 mice were used for all studies. Husbandry was approved by the 
IACUC and mice were housed in the Cal Poly vivarium in microisolator cages. Four 
mice were housed in each cage and provided food and water ad libitum. The following 
enrichment items were also included in all cages: nesting material, a mouse house, and a 
plastic tube. The room temperature was maintained at 73±5.0°F and lights were on a 12-
hour light dark cycle. The mice were checked on daily and inspected for health and 
proper access to food and water. Cages were changed every two weeks using aseptic 
methods.  
Surgical Procedures 
 In preparation for a femoral artery resection surgery,instruments were sterilized 
along with a surgery pack in an autoclave. The surgical area was sprayed down with 
Nolvosan and aseptic technique was used. The animal was weighed, anesthetized with 1-­‐3%,	  isoflurane	  gas	  at	  a	  flow	  rate	  of	  0.5-­‐1.0	  l·min-­‐1,	  and ear tagged. The hindlimbs of 
the animal were then shaved and coated with depilatory cream to remove the hair. The 
animal was then placed in the supine position on a heat pad under a dissection scope to 
maintain core body temperature at ~35°C. A small incision was made on the middle 
medial aspect of the thigh. A suture was tied around the femoral artery vein pair proximal 
to the muscular branch. Another suture was tied around the saphenous artery-vein pair, 
halfway between the knee and the ankle. The femoral artery vein pair was then dissected 
away from the skeletal muscle and removed, Figure 3. The incision was closed then 
closed with 6-0 polypropylene suture.	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 A sham surgery was then performed on the contralateral hindlimb. This consisted 
of an incision in the middle medial aspect of the thigh, blunt dissection of connective 
tissue, and suturing the incision. Following the procedure the animal was administered 
buprenorphine (0.075mg/kg) subcutaneously and allowed to become ambulatory. For a 
detailed description of the surgical procedure refer to Appendix A.  
Intravital Microscopy 
 The animal was then allowed to recover for a period of 14 days, at whichtime the 
animal was taken for an intravital measurement of the muscular branch diameter with the 
Microscan microscope. The Microscan microscope uses side-stream dark field 
microscopy (SDF) to detect the presence of hemoglobin, and is capable of visualizing 
vasculature from the size of capillaries to arteries. Therefore, it was used as an accurate 
way to measure the muscular branch diameter. (Refer to Appendix B for photos of the 
Microscan microscope and electrode setup).  
 An incision was made in the hindlimb to expose the muscular branch. Saline was 
continuously used to irrigate the exposed tissue to avoid desiccation. Two tungsten 
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microelectrodes were then placed on the mouse hindlimb. The stimulating electrode 
(negative) was placed just lateral to the muscular branch over the motor-end plate of the 
gracilis muscle and the ground electrode (positive) was placed subcutaneously near the 
knee. The hindlimb was restrained from movement by the placement of an anchored 
cotton swab on the knee of the animal. This allowed for an isometric contraction to 
decrease variability among animals.  
 A “test” stimulation for 3 seconds using 1mA for 500µs at a frequency of 8Hz 
(1mA, 100µs, 1Hz, 3sec) was given to ensure proper electrode placement. The Microscan 
was then placed over the muscular branch. Mineral oil was applied to the tissue and a 
small piece of plastic wrap was used to keep the mineral oil in place. The muscular 
branch was then allowed to stabilize for 30 minutes. After stabilization, a video of the 
muscular branch was recorded and used to measure artery diameter with AVA software. 
The muscle was then stimulated with a  (1mA, 500µs, 8Hz, 90sec)- high-intensity muscle 
contraction or (1mA, 200µs, 8Hz, 90sec)- moderate-intensity muscle contraction. 
Immediately, following the completion of electrical stimulation a second video was 
recorded with the Microscan to measure muscular branch artery diameter. This was 
repeated every two minutes until the diameter of the muscular branch returned to 
baseline. Once baseline was reached, the entire procedure was repeated on the 
contralateral hindlimb. The order of experimentation was randomized between the 
ischemic and non-ischemic hindlimb. For the pilot study, no resection surgery was 
performed on either hindlimb of the animal and all stimulations where performed using 
1mA, 500µs, 8Hz, and 90sec.  
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Data Analysis  	   The	  data	  was	  analyzed	  using	  a	  repeated	  measures	  ANOVA.	  Data	  is	  expressed	  as	  average	  values±	  standard	  error.	  	  P<	  0.05,	  indicated	  a	  significantdifference	  between	  control	  and	  ischemic	  artery	  diameter.	  The	  repeated	  measure	  ANOVA	  was	  used	  to	  determine	  an	  analysis	  of	  variance	  with	  a	  5%	  Least	  Significant	  Difference	  (LSD).	  The	  pilot	  study	  data	  was	  analyzed	  using	  a	  t-­‐Test,	  p<0.05	  indicated	  a	  significant	  difference.	  For	  a	  detailed	  description	  of	  the	  statistics	  used	  refer	  to	  Appendix	  C.	  
 
Results: 
 In order to show consistency among intravital measurements, a pilot study was 
performed in which the muscular branch diameter was measured from videos captured at 
rest and immediately after the cessation of electrical stimulation of the gracilis muscles 
(1mA, 500µs, 8Hz, 90sec), Figure 4. Measurements were made from both hindlimbs; the 
order of measurement was randomized between the right & left hindlimb using 4 animals. 
Resting diameter was 62.12± 2.44µm; functional vasodilation was 108.79± 4.39µm. 
There was a significant difference between the resting diameter and maximum functional 
vasodilation (*p<0.05). There was no statistical difference between the left and right 
limbs at rest or at maximum functional vasodilation (*p>0.05). 
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Figure 4: Pilot study vasodilation for muscular branch artery diameter measurement with 
the intravital Microscan. There was a significant difference between the rest and max 
dilation diameters. *p<	  0.05,	  indicated	  a	  significant	  difference.	  
 
 Functional vasodilation following ischemia was examined after verifying that 
consistent intravital measurements of arterial diameter could be performed. Using the 
Microscan intravital microscope, measurements from eight ischemic animals were 
conducted. The first set of experiments were designed to assess functional vasodilation in 
response to high-intensity muscle contraction. For this study, gracilis muscles in the 
ischemic limb and the sham limb each underwent a (1mA, 500µs, 8Hz, 90sec) 
stimulation, Figure 5 (order of stimulation was randomized). 
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Figure 5:Vasodilation response to high-intensity muscle contraction, 500µs duration 
stimulation(1mA, 500µs, 8Hz, 90sec) occurs at the zero time point. Vasodilation of the 
ischemic muscular branch collateral artery and the non-ischemic. n=8. = ischemic 
hindlimb. = sham hindlimb. *=statistical difference. *p<	  0.05,	  5%	  Least	  Significant	  Difference	  indicated	  a	  significant	  difference	  between	  control	  and	  ischemic	  artery	  diameter.	  
 
 The results of the high intensity muscle contraction show a similar vasodilation 
upon stimulation in the ischemicartery compared to the control; however, return to 
baseline diameter is impaired in the ischemic artery. 
 Functional vasodilationf ollowing ischemia was then assessed using a moderate-
intensity muscle contraction. Intravital measurements from six resected animals were 
conducted. For this study, the gracilis muscles in the ischemic limb and the sham limb 
each underwent a (1mA, 200µs, 8Hz, 90sec) stimulation, Figure 6 (order of stimulation 
was randomized). 
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Figure 6:Vasodilation response to moderate-intensity muscle contraction, 200µs duration 
stimulation (1mA, 200µs, 8Hz, 90sec) occurs at the zero time point. Vasodilation of the 
ischemic muscular branch collateral artery and the non-ischemic. n=6. = ischemic 
hindlimb. = sham hindlimb. *=statistical difference.*p	  <	  0.05,	  5%	  Least	  Significant	  Difference	  indicated	  a	  significant	  difference	  between	  control	  and	  ischemic	  artery	  diameter.	  
 
 The results from the moderate-intensity muscle contraction indicated there was a 
statistical difference between the ischemic and control artery diameter at rest, control 
diameter 50.13±3.89µm	  and	  ischemic	  diameter	  75.75±4.07µm. It also indicated the 
remodeled artery did not significantly change from baseline following stimulation. 
Vasodilation following moderate intensity stimulation was then normalized using a 
percent change from baseline, Figure 7. 
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Figure 7: Vasodilation response to moderate-intensity muscle contraction presented as 
percent change from baseline, 200µs duration stimulation(1mA, 200µs, 8Hz, 90sec) 
occurs at the zero time point. Vasodilation of the ischemic muscular branch collateral 
artery and the non-ischemic. n=6. = ischemic hindlimb. = sham hindlimb. 
*=statistical difference.*p	  <	  0.05,	  5%	  Least	  Significant	  Difference	  indicated	  a	  significant	  difference	  between	  control	  and	  ischemic	  artery	  diameter. 
 
 A percent change analysis indicated a statistical difference between the control 
and ischemic arteries following cessation of stimulus until the six-minute time point. This 
indicated the ischemic artery did not vasodilate in response to a moderate intensity 
muscle contraction.  
 
 
Discussion: 
 
 Ischemia produces a complex injury response that is difficult to treat. The effects 
of ischemia cause endothelial dysfunction, which results in decreased vasoactivity and an 
insufficient vascular growth response [11].. Those studies focusing on the vascular 
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growth response do not fully integrate maintaining the function of proper vasodilation 
into their proposed treatments [2, 10, 13]. However, it has been shown vasodilation has a 
critical role in recovering from ischemic injury [15]. This study takes a first step in 
understanding the response of arteries to ischemic injury in order to define the cause of 
abnormal vasoactivity and further to possibly develop treatments to correct the pathology.  
 Before examining the impact of ischemia on functional vasodilation it was 
important to ensure consistent measurements could be made, therefore, a pilot study was 
performed making intravital measurements of arterial diameter. The results had low 
variability indicating consistent measurements could be performed when adheringto the 
prescribed protocol, Figure 4. This provided confidence that the intravital measurements 
performed on the ischemic animals would be consistent and any variability would be due 
to the injury response and not the method of diameter measurement.  
 After establishing a consistent protocol, the impact of ischemia was determined. 
The hindlimb ischemia model results in reduced flow through the muscular branch artery 
and generally does not involve collateral enlargement. At high intensity skeletal muscle 
contraction, Figure 5 (1mA, 500µs, 8Hz, 90sec), the initial vasodilation in the ischemic 
artery is not different from the contralateral artery (avg± SE vs avg± SE). However, the 
ischemic arteries are refractory to regaining their resting diameter. The control artery 
returned to baseline diameter within 10-minutes following high-intensity muscle 
contraction, while the ischemic artery did not return to baseline after 25 minutes. 
 The ischemic artery may be unable to vasoconstrict due to improper function of 
adrenoreceptors in response to norepinephrine. Norepinephrine(NE) is a major 
vasoconstictor released by sympathetic neruons [8]. When metabolic factors due to 
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muscle stimulation override NE’s signaling to vasoconstrict, the vessel dilates. Following 
cessation of high intensity muscle stimulation the ischemic vessel is far less responsive to 
vasoconstriction than under normal conditions. Therefore, this abnormality may involve 
the adrenoreceptors response to NE. Additionally, there could also be continued oxygen 
demand in the recently exercised tissue. 
 Conversely, at moderate intensity skeletal muscle contraction, Figure 7 (1mA, 
200µs, 8Hz, 90sec), functional vasodilation was reduced compared to the contralateral 
limb (10.84 ± 8.79% versus 151.70 ± 22.15% increase above baseline). Under a moderate 
intensity muscle contraction there is a lesser degree of metabolic factors produced 
compared to a high intensity contraction. Therefore, the results indicate the need for a 
high level of recruitment for signaling vasodilators in order for the ischemic vessel to 
dilate. Further, it is hypothesized that the abnormal magnitude of functional vasodilation 
in the ischemic artery in response to high-intensity muscle contraction occurs via 
different vasodilator pathways than the sham-operated collateral artery. Under normal 
conditions when the muscles contract changes in Po2 and Pco2 along with a decrease in 
ATP signal for vasodilation [8]. Due to ischemia, the muscle is in a hypoxic environment, 
which can induce metabolic signaling due to low Po2 and high Pco2 at rest. Therefore, 
these metabolic factors are already present at rest. It is probable that additional pathways 
are signaling for vasodilation to occur in the ischemic artery upon muscle contraction 
compared to the control, which does not have the same metabolic signaling at rest. It is 
hypothesized that the reduced vasodilation in response to moderate intensity muscle 
contraction can be explained by impaired endothelial-dependent vasodilation. This is 
because the endothelium is the initiator for the smooth muscle to relax resulting in 
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vasodilation [15]. A lack of responsiveness to signaling pathways for vasodilation by the 
endothelium as a result of ischemia could be the cause of abnormal vasoactivity. 
 In order to test these hypotheses that impairment is due to reduced endothelial 
function, intravital microscopy will be used to measure vasodilation of the muscular 
branch artery in response to endothelial-specific and smooth muscle-specific 
pharmacological agents at day-14 following femoral artery resection. Endothelial-specific 
pharmacological agents will include acetylcholine (Ach), which activates nitric oxide 
synthase (NOS)to produce nitric oxide (NO) and signal the smooth muscle to relax [8]. 
This will allow for the evaluation of endothelium function based on the activation of 
NOS which is a prominent factor in vasodilation. Sodium	  nitroprusside	  (SNP)	  will	  also	  be	  used	  as	  it	  directly	  donates	  NO	  to	  smooth	  muscle.	  This	  will	  allow	  for	  evaluation	  of	  the	  smooth	  muscle’s	  response	  to	  NO. 
The hypothesis that α-adrenergic receptors are less responsive will be tested using 
the smooth muscle-specific pharmacological agent norepinephrine (NE). NE is known to 
act on the α1-adrenergic receptor and cause constriction. The targeted pathways of these 
pharmacologicalagents are prominent in the control of vasoactivity. Understanding the 
function of these pathways is critical to understanding the effects of ischemia. Once these 
pathways are understood others can be targeted.  
 The administration of these pharmacological agents will be performed using a 
superfusion system. This delivers a temperature controlled physiological salt solution. 
Pharmacological agents can be placed in the physiological solution, such as acetylcholine 
(Ach), delivered to the area of interest and the vessel’s vasoactivity can be measured. The 
superfusion system will be used in addition to the already described Microscan 
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microscope setup without the use of stimulating electrodes. Further investigation will 
utilize this system to deliver the prescribed pharmacological agents to the ischemic 
hindlimb and evaluate vasoactivity compared to the vasoactivity of the contralateral non-
ischemic hindlimb. This will indicate what pathway is affecting the vasodilation and 
vasoconstriction of the vessel. Identifying the role of these pathways will allow for 
evaluation of possible treatment methods to restore normal vasoactivity function.  
 Further studies could also include the evaluation of nitric oxide production of the 
ischemic hindlimb upon muscle stimulation. Diseased animals could be used to study the 
effects of ischemia under pathological conditions.  Exercise could be incorporated into 
the model used in this paper to examine the effects exercise has on ischemic injury. 
Electrical stimulation treatment could also be used in conjunction with this model to 
show the benefits of muscle activity, which is similar to exercise. Further molecular 
analysis could be conducted to evaluate the expression of genes under ischemic 
conditions. Gene therapy has been proposed as a possible treatment for ischemia [13]. 
 This animal model does contain limitations in studying the effects of ischemia. 
This study used young, otherwise healthy animals, while the largest percentage of 
patients affected by ischemia is in the aged adult population, who suffer from a number 
of wide ranging diseases and metabolic disorders [4]. However, it is important to 
understand the response to ischemia in healthy models to gain a further understanding of 
the ischemic response in unhealthy individuals. Further studies could be conducted with 
animals suffering from diabetes, obesity, high cholesterol, or hypertension. This initial 
study focuses on gaining and understanding of the ischemic injury response and every 
effort has been made to ensure accuracy in this study. 
	   22	  
 Chronic limb ischemia is a prevalent disease in the aged population with few 
treatment options. It is vital to understand the pathology of ischemia and mechanisms 
underlying the pathology. The promotion of vessel growth is a promising treatment 
options. However, it is vital to restore vasoactivity to the vasculature in conjunction with 
the promotion of vessel growth. This study demonstrated there is abnormal vasoactivity 
under ischemic conditions and will lead to future studies to define the underlying 
mechanism of abnormality. 
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Appendix A:Hindlimb Ischemia Surgery- Resection Checklist 
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Appendix B: Microscan Microscope and Electrode Setup 
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Appendix C:Statistics	  Protocol:	  Repeated	  Measures	  ANOVA	  	  
 Software:	  Minitab	  	  
• Open	  Minitab	  	  
• Input	  values	  for	  the	  Treatment	  groups	  first	  using	  the	  measured	  response,	  Y,	  at	  each	  time	  point	  in	  the	  columns	  as	  specified	  below	  using	  the	  exact	  wording	  then	  input	  the	  Control	  values	  beneath	  the	  Treatment	  values.	  The	  first	  column	  should	  be	  labeled	  “Subject”	  the	  second	  column	  is	  “TRT”	  the	  third	  is	  “Time”	  and	  the	  fourth	  is	  “Y”.	  Refer	  to	  the	  screenshots	  below.	  
	  
• Open	  Stat	  >	  ANOVA	  >	  General	  Linear	  Model	  
• Complete	  the	  following	  parameters:	  Model:	  TRT	  Subject(TRT)	  Time	  TRT*Time	  Random:	  Subject	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  Results:	  Display	  expected	  mean	  squares	  and	  least	  square	  means	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  TRT	  Time	  TRT*Time	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   Factors	  Plot:	  TRT	  Time	  Interaction	  Plot:	  TRT*Time	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• Once	  the	  ANOVA	  analysis	  is	  ran	  a	  table	  with	  control	  and	  treatment	  data	  at	  each	  time	  point	  is	  generated.	  	  
• The	  table	  should	  be	  recorded	  on	  a	  spreadsheet	  or	  paper	  for	  a	  manual	  comparison	  of	  values	  
• The	  estimate	  of	  standard	  error	  between	  two	  time	  means	  is	  then	  calculated	  using	  the	  formula	   where	  MSERROR(TIME)=	  the	  estimated	  error	  and	  N=#	  of	  subjects.	  
• Then	  using	  the	  t-­‐distribution	  calculate	  the	  degrees	  of	  freedom	  by	  the	  formula	  d*(n-­‐1)*(t-­‐1)	  where	  d=2,	  n=the	  number	  of	  subjects,	  and	  t=the	  number	  of	  time	  points	  measured	  
• Using	  this	  number	  look	  up	  the	  t	  value	  distribution	  in	  Minitab:	  	   	   Calc	  >Prob	  Dist	  >	  t	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• Using	  the	  t	  value	  compute	  LSD=(s.e.)*(t	  value)	  where	  LSD	  is	  the	  Least	  Significant	  Difference	  (95%	  Confidence	  Interval)	  
• Using	  the	  value	  compare	  the	  Control	  group	  within	  itself.	  	  For	  example	  compare	  the	  first	  time	  point	  to	  the	  second,	  then	  compare	  those	  to	  the	  third	  and	  so	  on.	  If	  the	  difference	  between	  the	  different	  time	  points	  is	  greater	  than	  the	  LSD	  then	  the	  values	  at	  the	  time	  points	  are	  significantly	  different.	  Complete	  the	  same	  process	  for	  the	  Treatment	  group.	  This	  test	  shows	  whether	  there	  is	  a	  significant	  change	  from	  baseline	  and	  a	  return	  to	  baseline.	  
• To	  complete	  the	  Comparison	  of	  Treatments	  at	  each	  time	  a	  similar	  method	  is	  used	  to	  the	  first	  comparison.	  However,	  instead	  of	  comparing	  within	  the	  Control	  or	  Treatment	  group	  the	  two	  groups	  are	  compared	  to	  each	  other.	  This	  will	  show	  if	  there	  is	  a	  significant	  difference	  between	  the	  two	  groups	  at	  the	  same	  time	  points.	  
• Construct	  a	  table	  of	  the	  Control	  and	  Treatment	  valves	  from	  the	  time	  points	  given	  from	  the	  results	  of	  the	  ANOVA	  test	  
• The	  standard	  error	  is	  
€ 
s.e.= 2[MSERROR(SUBJECT) + (t −1)MSERROR(TIME)N * t 	  where	  t	  =	  the	  number	  of	  time	  points	  and	  N	  =	  #	  of	  subjects.	  
• The	  approximate	  t	  value	  is	  calculated	  using	  the	  equation	  
€ 
t* =
t
.025 (d−1)( t−1)
MSE(SUBJ) + (t −1) t
.025 d (n−1)( t−1)
MSE(TIME)
MSE(SUBJ) + (t −1)MSE(TIME) 	  all	  of	  the	  t	  values	  can	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be	  generated	  from	  the	  t	  value	  distribution	  plot	  in	  Minitab	  as	  mentioned	  above.	  
• The	  LSD=(s.e.)(t*)	  with	  a	  95%	  confidence	  interval.	  This	  value	  will	  be	  used	  to	  compare	  the	  difference	  between	  the	  Control	  and	  the	  Treatment	  groups	  
• Use	  the	  table	  to	  compare	  the	  Control	  group	  to	  the	  Treatment	  group	  at	  each	  time	  point.	  If	  the	  difference	  between	  the	  two	  groups	  is	  greater	  than	  the	  LSD	  then	  the	  groups	  are	  significantly	  different.	  
 
Example Data Set: Importing	  this	  Data	  Set	  into	  Minitab	  will	  give	  the	  shown	  results	  Subject	   TRT	   Time	   Y	  1	   TRT	   -­‐1	   76.66	  1	   TRT	   0	   116.25	  1	   TRT	   2	   108.43	  1	   TRT	   4	   106.35	  1	   TRT	   6	   103.38	  1	   TRT	   8	   95.66	  1	   TRT	   10	   98.05	  2	   TRT	   -­‐1	   64.27	  2	   TRT	   0	   116.78	  2	   TRT	   2	   119.12	  2	   TRT	   4	   112.29	  2	   TRT	   6	   101.03	  2	   TRT	   8	   89.95	  2	   TRT	   10	   89.11	  3	   TRT	   -­‐1	   86.67	  3	   TRT	   0	   107.01	  3	   TRT	   2	   109.10	  3	   TRT	   4	   115.10	  3	   TRT	   6	   119.06	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3	   TRT	   8	   130.62	  3	   TRT	   10	   124.52	  4	   TRT	   -­‐1	   65.05	  4	   TRT	   0	   85.60	  4	   TRT	   2	   84.73	  4	   TRT	   4	   72.44	  4	   TRT	   6	   72.78	  4	   TRT	   8	   72.23	  4	   TRT	   10	   70.87	  5	   TRT	   -­‐1	   67.63	  5	   TRT	   0	   100.69	  5	   TRT	   2	   96.86	  5	   TRT	   4	   76.29	  5	   TRT	   6	   70.73	  5	   TRT	   8	   64.58	  5	   TRT	   10	   69.59	  6	   TRT	   -­‐1	   55.40	  6	   TRT	   0	   112.85	  6	   TRT	   2	   115.51	  6	   TRT	   4	   116.25	  6	   TRT	   6	   112.65	  6	   TRT	   8	   100.98	  6	   TRT	   10	   101.00	  7	   TRT	   -­‐1	   80.89	  7	   TRT	   0	   140.26	  7	   TRT	   2	   144.20	  7	   TRT	   4	   145.28	  7	   TRT	   6	   130.65	  7	   TRT	   8	   121.48	  7	   TRT	   10	   121.10	  8	   TRT	   -­‐1	   72.90	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8	   TRT	   0	   125.95	  8	   TRT	   2	   124.29	  8	   TRT	   4	   126.65	  8	   TRT	   6	   117.24	  8	   TRT	   8	   114.82	  8	   TRT	   10	   87.76	  1	   Con	   -­‐1	   74.23	  1	   Con	   0	   119.49	  1	   Con	   2	   111.92	  1	   Con	   4	   90.21	  1	   Con	   6	   79.16	  1	   Con	   8	   76.86	  1	   Con	   10	   76.86	  2	   Con	   -­‐1	   62.87	  2	   Con	   0	   118.63	  2	   Con	   2	   105.45	  2	   Con	   4	   93.61	  2	   Con	   6	   73.78	  2	   Con	   8	   77.03	  2	   Con	   10	   77.51	  3	   Con	   -­‐1	   56.41	  3	   Con	   0	   96.71	  3	   Con	   2	   79.72	  3	   Con	   4	   77.31	  3	   Con	   6	   64.16	  3	   Con	   8	   64.22	  3	   Con	   10	   58.13	  4	   Con	   -­‐1	   59.63	  4	   Con	   0	   105.97	  4	   Con	   2	   91.91	  4	   Con	   4	   77.87	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4	   Con	   6	   72.03	  4	   Con	   8	   60.35	  4	   Con	   10	   60.35	  5	   Con	   -­‐1	   76.20	  5	   Con	   0	   132.85	  5	   Con	   2	   120.63	  5	   Con	   4	   106.40	  5	   Con	   6	   91.87	  5	   Con	   8	   77.37	  5	   Con	   10	   76.93	  6	   Con	   -­‐1	   58.70	  6	   Con	   0	   141.28	  6	   Con	   2	   106.09	  6	   Con	   4	   87.83	  6	   Con	   6	   67.16	  6	   Con	   8	   58.76	  6	   Con	   10	   58.76	  7	   Con	   -­‐1	   57.91	  7	   Con	   0	   129.78	  7	   Con	   2	   80.89	  7	   Con	   4	   71.06	  7	   Con	   6	   65.00	  7	   Con	   8	   57.93	  7	   Con	   10	   57.93	  8	   Con	   -­‐1	   54.99	  8	   Con	   0	   129.63	  8	   Con	   2	   90.23	  8	   Con	   4	   81.47	  8	   Con	   6	   72.47	  8	   Con	   8	   66.02	  8	   Con	   10	   60.87	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  General	  Linear	  Model:	  Y	  versus	  TRT,	  Time,	  Subject	  	  Factor	  	  	  	  	  	  	  	  Type	  	  	  	  Levels	  	  Values	  TRT	  	  	  	  	  	  	  	  	  	  	  fixed	  	  	  	  	  	  	  	  2	  	  Con,	  TRT	  Subject(TRT)	  	  random	  	  	  	  	  	  16	  	  1,	  2,	  3,	  4,	  5,	  6,	  7,	  8,	  1,	  2,	  3,	  4,	  5,	  6,	  7,	  8	  Time	  	  	  	  	  	  	  	  	  	  fixed	  	  	  	  	  	  	  	  7	  	  -­‐1,	  0,	  2,	  4,	  6,	  8,	  10	  	  	  Analysis	  of	  Variance	  for	  Y,	  using	  Adjusted	  SS	  for	  Tests	  	  Source	  	  	  	  	  	  	  	  	  DF	  	  	  Seq	  SS	  	  	  AdjSS	  	  Adj	  MS	  	  	  	  	  	  F	  	  	  	  	  	  P	  TRT	  	  	  	  	  	  	  	  	  	  	  	  	  1	  	  	  9439.2	  	  	  9439.29439.2	  	  	  7.16	  	  0.018	  Subject(TRT)	  	  	  14	  	  18462.8	  	  18462.8	  	  1318.8	  	  16.91	  	  0.000	  Time	  	  	  	  	  	  	  	  	  	  	  	  6	  	  27389.827389.8	  	  4565.0	  	  58.55	  	  0.000	  TRT*Time	  	  	  	  	  	  	  	  6	  	  	  5180.8	  	  	  5180.8863.5	  	  11.07	  	  0.000	  Error	  	  	  	  	  	  	  	  	  	  84	  	  	  6549.7	  	  	  6549.7	  	  	  	  78.0	  Total	  	  	  	  	  	  	  	  	  111	  	  67022.4	  	  	  S	  =	  8.83020	  	  	  R-­‐Sq	  =	  90.23%	  	  	  R-­‐Sq(adj)	  =	  87.09%	  	  	  Unusual	  Observations	  for	  Y	  	  Obs	  	  	  	  	  	  	  	  Y	  	  	  	  	  	  Fit	  	  SE	  Fit	  	  Residual	  	  St	  Resid	  16	  	  107.010	  	  125.835	  	  	  4.415	  	  	  -­‐18.825	  	  	  	  	  -­‐2.46	  R	  17	  	  109.100	  	  125.442	  	  	  4.415	  	  	  -­‐16.342	  	  	  	  	  -­‐2.14	  R	  20	  	  130.620	  	  111.452	  	  	  4.415	  	  	  	  19.168	  	  	  	  	  	  2.51	  R	  21	  	  124.520	  	  107.912	  	  	  4.415	  	  	  	  16.608	  	  	  	  	  	  2.17	  R	  	  22	  	  	  65.050	  	  	  45.505	  	  	  4.415	  	  	  	  19.545	  	  	  	  	  	  2.56	  R	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  29	  	  	  67.630	  	  	  48.744	  	  	  4.415	  	  	  	  18.886	  	  	  	  	  	  2.47	  R	  	  36	  	  	  55.400	  	  	  72.782	  	  	  4.415	  	  	  -­‐17.382	  	  	  	  	  -­‐2.27	  R	  	  43	  	  	  80.890	  	  	  96.957	  	  	  4.415	  	  	  -­‐16.067	  	  	  	  	  -­‐2.10	  R	  	  56	  	  	  87.760	  	  104.702	  	  	  4.415	  	  	  -­‐16.942	  	  	  	  	  -­‐2.22	  R	  93	  	  141.280	  	  122.315	  	  	  4.415	  	  	  	  18.965	  	  	  	  	  	  2.48	  R	  100	  	  129.780	  	  114.018	  	  	  4.415	  	  	  	  15.762	  	  	  	  	  	  2.06	  R	  	  R	  denotes	  an	  observation	  with	  a	  large	  standardized	  residual.	  	  	  Expected	  Mean	  Squares,	  using	  Adjusted	  SS	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Expected	  Mean	  Square	  for	  	  	  	  Source	  	  	  	  	  	  	  	  Each	  Term	  1	  	  TRT	  	  	  	  	  	  	  	  	  	  	  (5)	  +	  7.0000	  (2)	  +	  Q[1,	  4]	  2	  	  Subject(TRT)	  	  (5)	  +	  7.0000	  (2)	  3	  	  Time	  	  	  	  	  	  	  	  	  	  (5)	  +	  Q[3,	  4]	  4	  	  TRT*Time	  	  	  	  	  	  (5)	  +	  Q[4]	  5	  	  Error	  	  	  	  	  	  	  	  	  (5)	  	  	  Error	  Terms	  for	  Tests,	  using	  Adjusted	  SS	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Synthesis	  	  	  	  Source	  	  	  	  	  	  	  	  Error	  DF	  	  Error	  MS	  	  of	  Error	  MS	  1	  	  TRT	  	  	  	  	  	  	  	  	  	  	  	  	  	  14.00	  	  	  	  1318.8	  	  (2)	  2	  	  Subject(TRT)	  	  	  	  	  84.00	  	  	  	  	  	  78.0	  	  (5)	  3	  	  Time	  	  	  	  	  	  	  	  	  	  	  	  	  84.00	  	  	  	  	  	  78.0	  	  (5)	  4	  	  TRT*Time	  	  	  	  	  	  	  	  	  84.00	  	  	  	  	  	  78.0	  	  (5)	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Variance	  Components,	  using	  Adjusted	  SS	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Estimated	  Source	  	  	  	  	  	  	  	  	  	  	  	  Value	  Subject(TRT)	  	  	  	  	  177.26	  Error	  	  	  	  	  	  	  	  	  	  	  	  	  77.97	  	  	  Least	  Squares	  Means	  for	  Y	  	  TRT	  	  	  	  	  	  	  	  	  Mean	  Con	  	  	  	  	  	  	  	  82.13	  TRT	  	  	  	  	  	  	  100.49	  Time	  -­‐1	  	  	  	  	  	  	  	  	  66.90	  	  0	  	  	  	  	  	  	  	  117.48	  	  2	  	  	  	  	  	  	  	  105.57	  	  4	  	  	  	  	  	  	  	  	  97.28	  	  6	  	  	  	  	  	  	  	  	  88.32	  	  8	  	  	  	  	  	  	  	  	  83.05	  10	  	  	  	  	  	  	  	  	  80.58	  TRT*Time	  Con	  -­‐1	  	  	  	  	  62.62	  Con	  	  0	  	  	  	  121.79	  Con	  	  2	  	  	  	  	  98.36	  Con	  	  4	  	  	  	  	  85.72	  Con	  	  6	  	  	  	  	  73.20	  Con	  	  8	  	  	  	  	  67.32	  Con	  10	  	  	  	  	  65.92	  TRT	  -­‐1	  	  	  	  	  71.18	  TRT	  	  0	  	  	  	  113.17	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TRT	  	  2	  	  	  	  112.78	  TRT	  	  4	  	  	  	  108.83	  TRT	  	  6	  	  	  	  103.44	  TRT	  	  8	  	  	  	  	  98.79	  TRT	  10	  	  	  	  	  95.25	  	  	  
 
